Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Consensus Target Price from Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given a consensus rating of “Buy” by the eight analysts that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $12.67.

Several research analysts have recently commented on the company. HC Wainwright assumed coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 target price on the stock. D. Boral Capital reissued a “buy” rating and issued a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. Finally, StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Immunic during the 3rd quarter worth $50,000. HB Wealth Management LLC bought a new stake in shares of Immunic in the 4th quarter valued at $81,000. Jane Street Group LLC increased its position in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares in the last quarter. Finally, State Street Corp increased its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Trading Down 1.3 %

IMUX stock opened at $0.94 on Thursday. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11. The business’s 50 day moving average is $1.05 and its 200-day moving average is $1.27.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.